The vaccine developed by the biotech american Moderna in partnership with the national Institutes of health (NIH) has triggered an immune response "robust" and prevented virus replication in the lungs and noses of monkeys, according to results published Tuesday.
This is one of the two vaccines western, with one of the university of Oxford/AstraZeneca, have started large-scale testing on thousands of human participants, so-called phase 3. The government of Donald Trump has invested nearly a billion dollars to support its development.